Operator
Okay. We are good to go. Welcome to this Novo Nordisk fireside at the 61st Edition of EASD here in Vienna. Welcome to all of you in the room and also welcome to those listening in online.
Today’s call will focus on the R&D and in the pipeline, and we’re here today with Martin, who will take us through some of the developments later. Before we get into it, just a usual word of caution in terms of the forward-looking statements and that the future is unpredictable, that pertains, in particular, when it comes to the pipeline.
In terms of the format, Martin will spend a few minutes on some opening remarks. After that, we’ll turn it to you in the room where we go around with 1 question each, and we’ll take the discussion where you would like to go. As said, we’ll focus the call on the pipeline and R&D events, both pertaining to the EASD, but also to the pipeline overall.
So with that, welcome, and over to you, Martin.
Martin Lange
EVP of R&D, CSO and Member of the Management Board
Thank you very much. So basically, I’ll just talk a little bit about the new R&D organization that has been created in Novo Nordisk. As you know, for the last
Read the full article here